|
8:00am-8:10am
|
Introduction
|
|
8:10am-8:35am
|
Use Of Checkpoint Inhibitor Therapy To Treat JC/BK Virus PML
Avindra Nath, MD, National Institutes of Health
|
|
8:35am-9:00am
|
Autoimmunity/Immune Dysregulation And Other Dark Sides Of Checkpoint Inhibitor Therapy
S. Lindsay Davis, MD, University of Colorado School of Medicine
|
|
9:00am-9:25am
|
Anti-CD20 Therapies—Are There Differences Between the Old and the New?
Maria Leandro, MD, PhD, University College London
|
|
9:25am-9:50am
|
Occurrence Of PML After B Cell Depletion Therapy
Yang Mao-Draayer, MD, PhD, University of Michigan
|
|
9:50am-10:10am
|
Coffee Break
|
|
10:10am-10:35am
|
Anti-IFNgamma Therapy and HLH
Michael Jordan, MD, Cincinnati Children’s Hospital Medical Center
|
|
10:35am-11:00am
|
Natural History and Infections In Patients With Anti IFN-Gamma Autoantibodies
Christa Zerbe, MD, NIAID/NIH
|
|
11:00am-11:25am
|
Use of Ruxolitinib to Treat HLH
Kim Nichols, MD, St. Jude Children's Research Hospital
|
|
11:25am-11:50am
|
Speaker TBD
|
|
11:50am-12:20pm
|
Lunch
|
|
12:20am-12:45pm
|
Use of mTOR Inhibitors To Treat Vascular Malformations
Joyce Teng, MD PhD, Stanford University
|
|
12:45pm-1:10pm
|
Use Of Eculizumab To Treat Myasthenia Gravis +/- Thymoma
James F. Howard Jr., MD, University of North Carolina
|
|
1:10pm-1:35pm
|
Infectious Risks Of Eculizumab Therapy
Lucy A. McNamara , PhD, National Center for Immunization and Respiratory Diseases, CDC
|
|
1:35pm-2:00pm
|
Speaker TBD
|
|
2:00pm-2:30pm
|
Speaker TBD
|
|
2:30pm-2:45pm
|
Break
|
|
